These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 34985992)

  • 41. Immune checkpoint inhibitors in advanced non-small cell lung cancer: A metacentric experience from India.
    Kumar S; Joga S; Biswas B; Dabkara D; Prasad KT; Singh N; Malik PS; Khurana S; Ganguly S; Muthu V; Batra U
    Curr Probl Cancer; 2020 Jun; 44(3):100549. PubMed ID: 32035693
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis.
    Mo DC; Huang JF; Luo PH; Huang SX; Wang HL
    Int Immunopharmacol; 2021 Jul; 96():107594. PubMed ID: 33798808
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
    Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
    Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
    Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
    Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
    Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
    Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunotherapy in advanced non-small-cell lung cancer with
    Liu F; Yuan X; Jiang J; Chu Q
    Immunotherapy; 2020 Nov; 12(16):1195-1207. PubMed ID: 32985295
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer.
    Cascone T; Weissferdt A; Godoy MCB; William WN; Leung CH; Lin HY; Basu S; Yadav SS; Pataer A; Mitchell KG; Khan MAW; Shi Y; Haymaker C; Solis LM; Parra ER; Kadara H; Wistuba II; Sharma P; Allison JP; Ajami NJ; Wargo JA; Jenq RR; Gibbons DL; Lee JJ; Swisher SG; Vaporciyan AA; Heymach JV; Sepesi B
    Nat Commun; 2021 Aug; 12(1):5045. PubMed ID: 34413300
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
    Buti S; Bersanelli M; Perrone F; Bracarda S; Di Maio M; Giusti R; Nigro O; Cortinovis DL; Aerts JGJV; Guaitoli G; Barbieri F; Ferrara MG; Bria E; Grossi F; Bareggi C; Berardi R; Torniai M; Cantini L; Sforza V; Genova C; Chiari R; Rocco D; Della Gravara L; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Citarella F; Russano M; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Follador A; Bisonni R; Tuzi A; Minuti G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Olmetto E; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Addeo A; Friedlaender A; Cannita K; Porzio G; Ficorella C; Carmisciano L; Pinato DJ; Mazzaschi G; Tiseo M; Cortellini A
    Eur J Cancer; 2021 Jun; 150():224-231. PubMed ID: 33934059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer.
    Hurkmans DP; Basak EA; Schepers N; Oomen-De Hoop E; Van der Leest CH; El Bouazzaoui S; Bins S; Koolen SLW; Sleijfer S; Van der Veldt AAM; Debets R; Van Schaik RHN; Aerts JGJV; Mathijssen RHJ
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461348
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
    Gelsomino F; Di Federico A; Filippini DM; Dall'Olio FG; Lamberti G; Sperandi F; Balacchi C; Brocchi S; Ardizzoni A
    Clin Lung Cancer; 2020 Mar; 21(2):e45-e48. PubMed ID: 31902695
    [No Abstract]   [Full Text] [Related]  

  • 52. Advancing non-small cell lung cancer treatment: the power of combination immunotherapies.
    Wu Y; Yu G; Jin K; Qian J
    Front Immunol; 2024; 15():1349502. PubMed ID: 39015563
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systematic review of radiomic biomarkers for predicting immune checkpoint inhibitor treatment outcomes.
    Zhang C; de A F Fonseca L; Shi Z; Zhu C; Dekker A; Bermejo I; Wee L
    Methods; 2021 Apr; 188():61-72. PubMed ID: 33271285
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
    Smit HJM; Aerts J; van den Heuvel M; Hiltermann TJN; Bahce I; Smit EF; Dingemans AC; Hendriks LE; Stigt JA; Schramel FMNH; van Tinteren H; Groen HJM;
    Lung Cancer; 2020 Feb; 140():107-112. PubMed ID: 31911323
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.
    Lo Russo G; Facchinetti F; Tiseo M; Garassino MC; Ferrara R
    Curr Oncol Rep; 2020 Apr; 22(5):41. PubMed ID: 32296957
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics.
    Mezquita L; Preeshagul I; Auclin E; Saravia D; Hendriks L; Rizvi H; Park W; Nadal E; Martin-Romano P; Ruffinelli JC; Ponce S; Audigier-Valette C; Carnio S; Blanc-Durand F; Bironzo P; Tabbò F; Reale ML; Novello S; Hellmann MD; Sawan P; Girshman J; Plodkowski AJ; Zalcman G; Majem M; Charrier M; Naigeon M; Rossoni C; Mariniello A; Paz-Ares L; Dingemans AM; Planchard D; Cozic N; Cassard L; Lopes G; Chaput N; Arbour K; Besse B
    Eur J Cancer; 2021 Jul; 151():211-220. PubMed ID: 34022698
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations.
    Zullo L; Rossi G; Dellepiane C; Tagliamento M; Alama A; Coco S; Longo L; Pronzato P; Maria A; Genova C
    Immunotherapy; 2021 Apr; 13(6):509-525. PubMed ID: 33626932
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.
    Calles A; Riess JW; Brahmer JR
    Am Soc Clin Oncol Educ Book; 2020 May; 40():372-384. PubMed ID: 32421452
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety of current immune checkpoint inhibitors in non-small cell lung cancer.
    Abdayem P; Planchard D
    Expert Opin Drug Saf; 2021 Jun; 20(6):651-667. PubMed ID: 33393387
    [No Abstract]   [Full Text] [Related]  

  • 60. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Huang J; Reckamp KL
    Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.